Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently hired a Contract Research Organization (โCROโ) for its third human pilot study. โThis marks a milestone for the company, notably since it announced its focus solely on glucagon-like peptide 1 (โGLP-1โ) studies for the 2024 calendar yearโฆ This randomized, crossover investigation will evaluate a dual-action GLP-1 + glucose-dependent insulintropic peptide (โGIPโ), specifically measuring absorption, tolerability, pharmacokinetics, and blood sugar levels. It will compare injected tirzepatide (Zepbound(R) by Eli Lilly) to a compound formulated, DehydraTECH-processed tirzepatide derived from Zepbound(R). The objective would be to evaluate whether DehydraTECH-processed tirzepatide, when taken orally, offers any absorption into the human bloodstream and, if so, how much,โ a recent article reads. โLexariaโs latest study in an oral capsule hopes to evidence improved tolerability while also producing measurable quantities of drug in blood. This will be Lexariaโs first-ever work with the tirzepatide molecule and, as such, any noteworthy delivery of tirzepatide through oral delivery could be a significant finding,โ said Chris Bunka, Lexariaโs CEO.
To view the full article, visit https://ibn.fm/VpJ54
About Lexaria Bioscience Corp.
DehydraTECH(TM) is Lexariaโs patented drug delivery formulation and processing platform technology that improves the way active pharmaceutical ingredients (โAPIsโ) enter the bloodstream through oral delivery. Since 2016, Lexaria has developed and investigated DehydraTECH with a variety of beneficial molecules in oral and topical formats. DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption and has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier, which Lexaria believes to be of particular importance for centrally active compounds. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 46 patents granted and many patents pending worldwide. For more information, visit the companyโs website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the companyโs newsroom at https://ibn.fm/LEXX
About TinyGems
TinyGemsย is a specialized communications platform with a focus on innovative small-cap and mid-cap companies with bright futures and huge potential. It is one of 60+ brands withinย theย Dynamic Brand Portfolioย @ย IBNย that delivers:ย (1) access to a vast network of wire solutions viaย InvestorWireย to efficiently and effectively reach a myriad of target markets, demographics and diverse industries;ย (2) article andย editorial syndication to 5,000+ outlets;ย (3) enhancedย press release enhancementย to ensure maximum impact;ย (4)ย social media distributionย via IBN to millions of social media followers;ย and (5) a full array of tailoredย corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TinyGems is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in todayโs market, TinyGems brings its clients unparalleled recognition and brand awareness. TinyGems is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TinyGems, text โGemsโ to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visitย https://www.TinyGems.com
Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published:ย https://www.TinyGems.com/Disclaimer
TinyGems
Los Angeles, CA
www.TinyGems.com
310.299.1717 Office
Editor@TinyGems.com
TinyGems is powered byย IBN
